Uncategorized
Progress slow but steady for cell, gene therapies for AMD
WAIKOLOA, Hawaii — Progress in cell and gene therapies for the treatment of wet and dry age-related macular degeneration is evidenced by advancement, albeit slow, of clinical trials, according to a speaker here.Janssen and Ocata are both initiating phase 2 trials of cell therapy for atrophic AMD, and a phase 2 study of NeuroTech’s implant platform that combines cell and gene therapy for treatment of wet AMD is ongoing, Allen C. Ho, MD, told colleagues at Retina 2016.